Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Current Leases (2019 - 2025)

Puma Biotechnology (PBYI) has disclosed Current Leases for 7 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases fell 76.28% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Dec 2025, down 76.28%, and an annual FY2025 reading of $1.3 million, down 76.28% over the prior year.
  • Current Leases was $1.3 million for Q4 2025 at Puma Biotechnology, down from $2.5 million in the prior quarter.
  • Across five years, Current Leases topped out at $5.7 million in Q1 2025 and bottomed at $1.3 million in Q4 2025.
  • Average Current Leases over 5 years is $4.1 million, with a median of $4.2 million recorded in 2022.
  • The sharpest move saw Current Leases grew 17.73% in 2021, then crashed 76.28% in 2025.
  • Year by year, Current Leases stood at $3.6 million in 2021, then grew by 15.84% to $4.1 million in 2022, then grew by 15.94% to $4.8 million in 2023, then rose by 15.42% to $5.5 million in 2024, then plummeted by 76.28% to $1.3 million in 2025.
  • Business Quant data shows Current Leases for PBYI at $1.3 million in Q4 2025, $2.5 million in Q3 2025, and $4.4 million in Q2 2025.